JP2006052208A - Prophylactic and therapeutic agent of thrombus/embolus by oral administration - Google Patents

Abstract

<P>PROBLEM TO BE SOLVED: To provide an excellent prophylactic and therapeutic agent of thrombus/embolus of an antiplatelet drug, capable of manifesting antithrombic activities equal to or more than the case of using a usual dose by the dose in an amount smaller than the amount required for singly exhibiting sufficient effects by effectively using an orally administrable antiplatelet drug. <P>SOLUTION: The orally administrable prophylactic and therapeutic agent of the thrombus/embolus contains a compound represented by general formula (1) (wherein, Q<SP>1</SP>to Q<SP>4</SP>and R<SP>1</SP>to R<SP>2</SP>are each a substituent group) and an antiplatelet drug selected from aspirin, sarpogrelate, limaprost, cilostazol and the like as active ingredients. <P>COPYRIGHT: (C)2006,JPO&NCIPI

Description

  The present invention relates to a prophylactic / therapeutic agent for thrombus / embolism by oral administration.

  As antiplatelet drugs, drugs such as ticlopidine (2a), clopidogrel (2b), aspirin (4), sarpogrelate (5), limaprost (6), cilostazol (7) are clinically used in various countries, and blood clots and emboli It is effective in preventing and treating ischemic heart disease and cerebral infarction caused by.

It is known that ticlopidine (2a), clopidogrel (2b), aspirin (4), sarpogrelate (5), limaprost (6), and cilostazol (7) are useful as antithrombotic agents (Non-Patent Documents 1 to 3). 6). Among them, the usefulness of aspirin (4) has been proved by a large-scale clinical trial Antiplatelet Triallist 'Collaboration (Non-patent Document 7), and the usefulness of clopidogrel (2b) is also large-scale clinical trial CAPRIE study (non-patent It is proved in reference 8). However, in order to further enhance the effects of prevention and treatment of thrombosis and embolism, it is necessary to devise new drug development and drug administration methods.

As one of the contrivances of the drug administration method, a method of administering an antiplatelet drug in combination with an anticoagulant or an Xa inhibitor can be considered, and a combination of an antiplatelet drug and an anticoagulant (Patent Document 1) or an antiplatelet drug is considered. And a combination of Xa inhibitors (Patent Document 2) are known. However, in the former, low molecular weight heparin is used as an anticoagulant and glycoprotein IIb / IIIa antagonist (GPIIb / IIIa antagonist) is used as an antiplatelet agent. It is difficult to administer over a long period, not a drug. In the latter, ticlopidine (2a) and clopidogrel (2b) that can be administered orally are used as antiplatelet drugs, but pentasaccharides that cannot be administered orally are used as Xa inhibitors. In such a conventional technique, it is impossible to prevent and treat thrombus / embolism by administering antiplatelet drugs and anticoagulants or Xa inhibitors in combination over a long period of time.
In addition, when a plurality of drugs are used in combination as described above, it is widely known that it is generally necessary to pay attention to a drug interaction between these drugs. There are various types of liver metabolic enzymes (CYP) involved in drug metabolism (CYP3A4, CYP2C19, CYP2D6, CYP1A2, CYP2C9, CYP2E1, CYP3A, etc.), and when a drug inhibits any of these CYPs, It may cause serious side effects such as inhibiting the metabolism of the other drug used in combination and raising the blood concentration more than necessary. For example, ticlopidine, an antiplatelet drug, is known to inhibit CYP2C19 and CYP2D6 (Non-patent Document 9). In addition, cilostazol, which is also an antiplatelet drug, is metabolized by CYP3A4 and CYP2C19, and when used in combination with a drug that inhibits CYP3A4 or CYP2C19, drug interaction may occur. Therefore, for example, in the United States, when cilostazol is used in combination with a CYP3A4 inhibitor or a CYP2C19 inhibitor, it is recommended to reduce the dose of cilostazol (Non-patent Document 10).
US Pat. No. 6,103,705 International Publication No. 98-56365 Pamphlet Thrombosis Research, 17, 663-671 (1980) Thrombosis Haemostasis, 70, 812-816 (1993) Lancet, 257, 1172-1174 (1949) Thrombosis Haemostasis, 66, 484-488 (1991) Atherosclerosis Thrombosis, 13, 563-570 (1993) J. et al. Pharmacol. Exper. Ther. , 255, 1210-1217 (1990) BMJ, 308, 81-106 (1994) Lancet, 348, 1329-1339 (1996). Br. J. et al. Clin. Pharmacol. , 49, 343-351 (2000) American Journal of Cardiovascular Drugs, 3 (2), 117-138 (2003)

  The object of the present invention is to use an orally administrable antiplatelet drug more effectively, and administer at a dose smaller than the amount necessary to show a sufficient effect by itself, and is equivalent to using a normal dose An object of the present invention is to provide an excellent prophylactic / therapeutic agent for thrombus / embolism that can exhibit the above antithrombotic action.

  Therefore, the present inventor diligently studied a prophylactic / therapeutic agent for thrombosis / embolism comprising an antiplatelet drug and an Xa inhibitor as active ingredients. As a result, a specific antiplatelet drug and a compound represented by the following general formula (1) were obtained. When used in combination, oral administration is possible, and antiplatelet drugs can be administered at a dose smaller than the amount necessary to show sufficient effects, and an antithrombotic effect equivalent to or higher than that obtained when using a normal dose can be achieved. In addition, the prevention and treatment of thrombosis and embolism that can be administered for a long time with reduced side effects of antiplatelet drugs can be obtained. Furthermore, in general, when multiple drugs are used in combination, drug interaction is a concern. Since the Xa inhibitor described by the formula (1) is metabolically stable and does not have an inhibitory action on metabolic enzymes, it is extremely unlikely to cause drug interaction even when used in combination with an antiplatelet drug. Heading, present invention Completed.

  That is, the present invention is selected from a compound represented by the general formula (1), aspirin, sarpogrelate, limaprost, cilostazol, a compound represented by the general formula (2), and a compound represented by the general formula (3). The present invention provides a prophylactic / therapeutic agent for oral administration of thrombi and emboli containing an antiplatelet drug as an active ingredient.

Wherein Q ¹ is a 4,5,6,7-tetrahydrothiazolo [5,4-c] pyridin-2-yl group, which may have 1 to 2 substituents, 6,7-tetrahydrothiazolo [4,5-c] pyridin-2-yl group, 4,5,6,7-tetrahydrothieno [2,3-c] pyridin-2-yl group, 4,5,6 , 7-tetrahydrooxazolo [5,4-c] pyridin-2-yl group, 4,6-dihydro-5H-pyrrolo [3,4-d] thiazol-2-yl group, dihydropyrrolo [3,4 d] pyrimidin-2-yl group, 4,5,6,7-tetrahydrothiazolo [4,5-d] pyridazin-2-yl group, 4,5,6,7-tetrahydrooxazolo [4.5- d] pyridazin-2-yl group, 4,5,6,7-tetrahydrobenzo [d] thiazol-2- Indicates group or dihydro -4H- pyrano [4,3-d] thiazol-2-yl group;

Q ² is an alkylene group having 1 to 8 carbon atoms or a group — (CH ₂ ) pA— (CH ₂ ) q— (in the group, p and q are each independently an integer of 1 to 3 (provided that p And A represents a oxygen atom, a nitrogen atom, a sulfur atom, —SO—, —SO ₂ —, or —NH—.
Indicates;

R ¹ and R ² are each substituted with a ring containing Q ² and each independently represents a hydrogen atom, hydroxyl group, amino group, carboxyl group, oxo group, alkyl group, halogenoalkyl group, acyl group, alkoxy group, alkoxyalkyl group , Hydroxyalkyl group, carboxyalkyl group, alkoxycarbonyl group, alkoxycarbonylalkyl group, optionally substituted acylamino group, acylaminoalkyl group, aminoalkyl group, N-alkylaminoalkyl group, N, N-dialkyl Aminoalkyl group, N-alkoxycarbamoyl group, N-alkyl-N-alkoxycarbamoyl group, carbazoyl group optionally having 1 to 3 alkyl groups, alkylsulfonyl group, alkoxycarbonylamino group, carbamoyl group, alkyl group N-alkyl which may have a substituent on Moyl group, N, N-dialkylcarbamoyl group which may have a substituent on the alkyl group, alkylsulfonylamino group, alkoxycarbonylalkylsulfonyl group, carboxyalkylsulfonyl group, alkoxycarbonylacyl group, alkoxyalkylsulfonyl group or substituted 3 to 6-membered heterocyclic carbonyl group which may have a group. );

Q ³ is a carbonyl group, a sulfonyl group, —C (═O) —C (═O) —NH—, —C (═S) —C (═O) —NH—, —C (═O) —C (= S) -NH- or -C (= S) -C (= S) -NH- is shown;

Q ⁴ may have 1 to 2 substituents, phenyl group, naphthyl group, pyridyl group, pyrimidinyl, pyrazinyl group, pyridazinyl group, indolyl group, benzothienyl group, benzofuranyl group, benzoimidazolyl group, quinolyl group, An isoquinolyl group, a cinnolyl group, a thienyl group, a furyl group, a thiazolyl group, an oxazolyl group or a styryl group; ),

(Wherein R ¹⁰¹ represents a hydrogen atom, a lower alkyl group, a lower alkoxycarbonyl group or a lower alkylcarbonyl group, R ¹⁰² and R ¹⁰³ each independently represent a hydrogen atom, a lower alkyl group or a halogen atom, R ¹⁰⁴ represents a hydrogen atom, a hydroxyl group or a lower alkylcarbonyloxy group).

(Wherein R ¹⁰⁵ represents a hydrogen atom, a lower alkyl group, a lower alkoxycarbonyl group or a lower alkylcarbonyl group, R ¹⁰⁶ and R ¹⁰⁷ each independently represents a hydrogen atom, a lower alkyl group or a halogen atom, R ¹⁰⁸ represents a hydrogen atom or a lower alkyl group, and R ¹⁰⁹ represents a hydrogen atom or a lower alkylcarbonyl group.

  The present invention uses an orally administrable antiplatelet drug in combination with an orally administrable Xa inhibitor, so that even if the dose of the antiplatelet drug is lowered, the antiplatelet drug is more effective than that obtained by administration of a normal dose of the antiplatelet drug. Since thrombotic action can be expressed, side effects are reduced, and there is no drug interaction between both drugs, the prophylactic and therapeutic agent for oral administration of thrombosis / embolism of the present invention is unstable and narrow due to thrombosis / emboli. Heart disease, cerebral infarction, cerebral embolism, myocardial infarction, pulmonary infarction, pulmonary embolism, Buerger's disease, deep vein thrombosis, generalized intravascular coagulation syndrome, thrombus formation after replacement of prosthetic valve, reconstruction after revascularization It is useful for prevention and treatment of occlusion and thrombus formation during extracorporeal circulation.

  The compound represented by the general formula (1) used in the present invention is known as an Xa inhibitor and can be produced by the method described in WO 03/000680 or a method analogous thereto.

As the substituent for Q ^1, a linear, branched or cyclic alkyl group having 1 to 6 carbon atoms (hereinafter, referred to as a C _{1 to} C ₆ alkyl group may be referred to as a linear or branched group). And, for example, a linear or branched C ₁ -C ₆ alkyl group such as methyl group, ethyl group, isopropyl group, tert-butyl group, cyclopropyl group, cyclobutyl group, cyclopentyl group , 1-methylcyclopropyl C ₃ -C ₆ cycloalkyl group such as a group), C ₃ -C ₆ cycloalkyl C ₁ -C ₆ alkyl group (e.g., cyclopropylmethyl group, etc.), halogenoalkyl groups (for example, fluoro ethyl, chloroethyl group, etc.), hydroxy C ₁ -C ₆ alkyl group (e.g., hydroxyethyl group, 1,1-dimethyl-2-hydroxyethyl group, etc.), C ₁ -C ₆ alkoxy group (e.g., methoxy Group, ethoxy group, etc.), C ₁ -C ₆ alkoxy C ₁ -C ₆ alkyl group, a carboxyl group, C ₂ -C ₆ carboxyalkyl group (e.g., carboxymethyl group, etc.), C ₂ -C ₆ alkoxycarbonyl C ₁ -C ₆ alkyl group (e.g., methoxycarbonyl methyl group, tert- butoxycarbonyl methyl group, etc.), C ₂ -C ₆ alkoxycarbonyl amidino group which group is substituted, C ₂ -C ₆ alkenyl group (e.g., vinyl group, allyl Group), C ₂ -C ₆ alkynyl group (eg, ethynyl group, propynyl group, etc.), C ₂ -C ₆ alkoxycarbonyl group (eg, methoxycarbonyl group, ethoxycarbonyl group, tert-butoxycarbonyl group, etc.), amino C ₁ -C ₆ alkyl group (e.g., aminomethyl group, such as aminoethyl groups), C ₁ -C ₆ alkylamino C ₁ -C ₆ A Kill group (e.g., N- methylaminomethyl group, N- ethylaminomethyl group, etc.), di (C ₁ -C ₆ alkyl) amino C ₁ -C ₆ alkyl group (e.g., N, N- dimethylaminomethyl group, N, N-diethylaminomethyl group, N-ethyl-N-methylaminoethyl group, etc.), C ₂ -C ₆ alkoxycarbonylamino C ₁ -C ₆ alkyl group (for example, methoxycarbonylaminoethyl group, tert-butoxycarbonylamino) Ethyl group, etc.), C ₁ -C ₆ alkanoyl group (eg, formyl group, acetyl group, methylpropionyl group, cyclopentanecarbonyl group, etc.), C ₁ -C ₆ alkanoylamino C ₁ -C ₆ alkyl group (eg, acetyl) aminomethyl group, etc.), C ₁ -C ₆ alkylsulfonyl group (e.g., such as a methanesulfonyl group), C ₁ -C ₆ alkylsulfanyl Niruamino C ₁ -C ₆ alkyl group (e.g., such as methanesulfonylamino methyl group), a carbamoyl group, C ₁ -C ₆ alkylcarbamoyl group (e.g., methylcarbamoyl group, ethylcarbamoyl group, isopropylcarbamoyl group, tert- butylcarbamoyl group Etc.), N, N-di (C ₁ -C ₆ alkyl) carbamoyl group (eg dimethylcarbamoyl group, diethylcarbamoyl group, methylethylcarbamoyl group etc.), C ₁ -C ₆ alkylamino group (eg N-methyl) Amino group, N-ethylamino group, etc.), di (C ₁ -C ₆ alkyl) amino group (eg, N, N-dimethylamino group, N, N-diethylamino group, N-ethyl-N-methylamino group, etc.) ) 5- to 6-membered heterocyclic groups containing one or two of the same or different nitrogen, oxygen or sulfur atoms (eg , Pyrrolidinyl group, piperidinyl group, piperazinyl group, morpholinyl group, pyridyl group, pyrimidinyl group, tetrahydropyranyl group), the above 5-6 membered heterocyclic group -C ₁ -C ₄ alkyl group (e.g., morpholinomethyl group etc.) and heterocyclic groups of 5-6 membered - amino -C ₁ -C ₄ alkyl group (e.g., N- (oxazol-2-yl) and the like aminomethyl group).

If a specific example of Q ¹ is shown, 4,5,6,7-tetrahydrothiazolo [5,4-c] pyridin-2-yl group, 5-cyclopropyl-4,5,6,7-tetrahydrothia Zolo [5,4-c] pyridin-2-yl group, 5-carboxymethyl-4,5,6,7-tetrahydrothiazolo [5,4-c] pyridin-2-yl group, 5-butyl-4 , 5,6,7-tetrahydrothiazolo [5,4-c] pyridin-2-yl group, 5- (4-pyridyl) -4,5,6,7-tetrahydrothiazolo [5,4-c] Pyridin-2-yl group, 5-methyl-4,5,6,7-tetrahydrothiazolo [5,4-c] pyridin-2-yl group, 5- (4-pyridyl) -4,5,6 7-tetrahydrothiazolo [5,4-c] pyridin-2-yl group, 5-methyl-4,5,6,7 Tetrahydrothiazolo [4,5-c] pyridin-2-yl group, 6-methyl-4,5,6,7-tetrahydrothieno [2,3-c] pyridin-2-yl group, 5-methyl-4 , 5,6,7-tetrahydrooxazolo [5,4-c] pyridin-2-yl group, 5-methyl-4,6-dihydro-5H-pyrrolo [3,4-d] thiazol-2-yl group 5,7-dihydro-6-methylpyrrolo [3,4-d] pyrimidin-2-yl group, 5,6-dimethyl-4,5,6,7-tetrahydrothiazolo [4,5-d] pyridazine- 2-yl group, 5,6-dimethyl-4,5,6,7-tetrahydrooxazolo [4.5-d] pyridazin-2-yl group, 5-dimethylamino-4,5,6,7-tetrahydro Benzo [d] thiazol-2-yl group, 6,7-dihydro-4 H-pyrano [4,3-d] thiazol-2-yl group and the like can be mentioned.

Examples of the ring substituents R ¹ and R ² containing Q ² include the following.
Examples of the alkyl group include linear, branched, or cyclic C ₁ -C ₆ alkyl groups (for example, methyl group, cyclopropyl group, isobutyl group, etc.).

  Examples of the halogenoalkyl group include those in which 1 to 3 fluorine atoms, chlorine atoms, or bromine atoms are substituted on the above alkyl group (for example, chloromethyl group, 1-bromoethyl group, trifluoromethyl group, etc.). .

The acyl groups include alkanoyl groups C ₁ -C _6. Examples of the alkoxy group include linear, branched or cyclic C _{1 to} C ₆ alkoxy groups (for example, methoxy group, cyclopropoxy group, isopropoxy group and the like).

As the alkoxyalkyl group, the above C ₁ -C ₆ which one C ₁ -C ₆ alkoxy groups of the alkyl group is substituted (e.g., methoxymethyl group, ethoxymethyl group, etc.).

Examples of the hydroxyalkyl group include those in which one hydroxyl group is substituted on the above C ₁ -C ₆ alkyl group (for example, hydroxymethyl group, 1-hydroxyethyl group, etc.).

Examples of the carboxyalkyl group include those in which one carboxyl group is substituted on the above C ₁ -C ₆ alkyl group (for example, carboxymethyl group, 1-carboxyethyl group, etc.).

Arco The alkoxycarbonyl group, the above C ₁ -C ₆ alkoxy group and a carbonyl group group consisting of (for example, methoxycarbonyl group, ethoxycarbonyl group, etc.).

Examples of the alkoxycarbonylalkyl group include those in which one of the above alkoxycarbonyl groups is substituted on the above C ₁ -C ₆ alkyl group (for example, methoxycarbonylethyl group, ethoxycarbonylethyl group, etc.).

The acylamino group which may have a substituent includes, in addition to those in which the above C ₁ -C ₆ acyl group is substituted with an amino group (for example, formylamino group, acetylamino group, etc.), a halogen atom on the acyl group. atom, hydroxyl group, C ₁ -C ₆ alkoxy group, an amino group, N-C _{1 ~C 6} alkyl amino group, N, N-di -C ₁ -C ₆ alkylamino group, a carboxyl group, C ₂ -C ₆ alkoxy An acyl group (for example, 2-methoxyacetylamino group, 3-aminopropionylamino group, etc.) substituted with one or more carbonyl groups and the like can be mentioned.

Examples of the acylaminoalkyl group include those in which the above C ₁ -C ₆ acylamino group is substituted with the above C ₁ -C ₆ alkyl group (for example, formylaminomethyl group, acetylaminomethyl group, etc.).

Examples of the aminoalkyl group include those in which one amino group is substituted on the above C ₁ -C ₆ alkyl group (for example, aminomethyl group, 1-aminoethyl group, etc.).

The N-alkylaminoalkyl group is a group in which one C ₁ -C ₆ alkyl group is substituted on the nitrogen atom of an amino-C ₁ -C ₆ alkyl group (for example, N-methylaminomethyl group, N-methylamino Ethyl group).

As the N, N-dialkylaminoalkyl group, a group in which two C ₁ -C ₆ alkyl groups are substituted on the nitrogen atom of an amino-C ₁ -C ₆ alkyl group (for example, N, N-dimethylaminomethyl group, N-ethyl-N-methylaminoethyl group, etc.).

Examples of the N-alkoxycarbamoyl group include those in which a linear or branched C ₁ -C ₆ alkoxy group is substituted with a carbamoyl group (for example, a methoxycarbamoyl group).

Examples of the N-alkyl-N-alkoxycarbamoyl group include linear or branched C ₁ -C ₆ alkoxy groups and C ₁ -C ₆ alkyl groups substituted by carbamoyl groups (for example, N-ethyl-N -Methoxycarbamoyl group etc.).

The carbazoyl group which may have 1 to 3 alkyl groups includes a carbazoyl group substituted with _{1 to} 3 linear or branched C _{1 to} C ₆ alkyl groups in addition to the carbazoyl group ( For example, 1-methylcarbazoyl group, 1,2-dimethylcarbazoyl group, etc.) can be mentioned.

The alkylsulfonyl group, a linear, branched or cyclic C ₁ -C ₆ alkylsulfonyl group (e.g., methanesulfonyl group, etc.).

Examples of the alkoxycarbonylamino group include those obtained by substituting one C ₁ -C ₆ alkoxycarbonyl group on the amino group (for example, methoxycarbonylamino group, tert-butoxycarbonylamino group, etc.).

May have a substituent N- alkylcarbamoyl group on the alkyl group, hydroxy group, amino group, N-C ₁ ~C ₆ alkyl amino group, amidino group, a halogen atom, a carboxyl group, a cyano group, a carbamoyl group C ₁ -C ₆ alkoxy group, C ₁ -C ₆ alkanoyl group, C ₁ -C ₆ alkanoylamino group, C ₁ -C ₆ alkylsulfonylamino group, etc. A carbamoyl group substituted with a C ₁ -C ₆ alkyl group in the form of a ring or a ring, such as N-methylcarbamoyl group, N-ethylcarbamoyl group, N-isopropylcarbamoyl group, N-cyclopropylcarbamoyl group, N- ( 2-hydroxyethyl) carbamoyl group, N- (2-fluoroethyl) carbamoyl group, N- (2-cyanoethyl) carbamoyl group, N- (2 Methoxyethyl) carbamoyl group, N- carboxymethyl-methylcarbamoyl group, N- (2- aminoethyl) carbamoyl group, N- (2-Amijinoechiru) carbamoyl group, and the like.

Which may have a substituent on the alkyl group N, the N- dialkylcarbamoyl group, hydroxy group, amino group, N-C ₁ ~C ₆ alkyl amino group, amidino group, a halogen atom, a carboxyl group, a cyano group , A carbamoyl group, a C ₁ -C ₆ alkoxy group, a C ₁ -C ₆ alkanoyl group, a C ₁ -C ₆ alkanoylamino group, a C ₁ -C ₆ alkylsulfonylamino group, etc. Represents a carbamoyl group substituted with two branched or cyclic C ₁ -C ₆ alkyl groups, such as N, N-dimethylcarbamoyl group, N, N-diethylcarbamoyl group, N-ethyl-N-methyl, Carbamoyl group, N-isopropyl-N-methylcarbamoyl group, N- (2-hydroxyethyl) -N-methylcarbamoyl group, N, N-bis (2-hydroxyethyl) ca Vamoyl group, N, N-bis (2-fluoroethyl) carbamoyl group, N- (2-cyanoethyl) -N-methylcarbamoyl group, N- (2-methoxyethyl) -N-methylcarbamoyl group, N-carboxymethyl -N-methylcarbamoyl group, N, N-bis (2-aminoethyl) carbamoyl group and the like can be mentioned.

The alkylsulfonylamino group, those with one alkylsulfonyl group having C ₁ -C ₆ alkyl group described above is substituted with an amino group (e.g., methylsulfonylamino group, isopropylsulfonyl amino group, etc.).

Examples of the alkoxycarbonylalkylsulfonyl group include groups composed of the above C ₁ -C ₆ alkoxycarbonylalkyl group and a sulfonyl group (for example, methoxycarbonylethylsulfonyl group, ethoxycarbonylethylsulfonyl group, etc.).

  Examples of the carboxyalkylsulfonyl group include groups composed of the above carboxyalkyl group and sulfonyl group (for example, carboxymethylsulfonyl group, carboxyethylsulfonyl group, etc.).

  Examples of the alkoxycarbonylacyl group include groups composed of the above alkoxycarbonylalkyl group and carbonyl group (for example, methoxycarbonylmethylcarbonyl group, ethoxycarbonylmethylcarbonyl group, etc.).

Examples of the alkoxyalkylsulfonyl group include groups composed of the above C ₁ -C ₆ alkoxyalkyl group and a sulfonyl group (for example, a methoxymethylsulfonyl group, an ethoxyethylsulfonyl group, etc.).

  Examples of the carboxyalkylsulfonyl group include groups composed of the above carboxyalkyl group and sulfonyl group (for example, carboxymethylsulfonyl group, carboxyethylsulfonyl group, etc.).

The 3- to 6-membered heterocyclic carbonyl group which may have a substituent is a group composed of a saturated or unsaturated heterocyclic ring and a carbonyl group, and the heterocyclic ring has 1 to 3 heteroatoms (nitrogen atoms). , An oxygen atom, a sulfur atom, etc.) and a heterocyclic group having a substituent such as a hydroxy group, a halogen atom, an amino group, or a C ₁ -C ₆ alkyl group. Specifically, aziridinylcarbonyl group, azetidinylcarbonyl group, 3-hydroxyazetidinylcarbonyl group, 3-methoxyazetidinylcarbonyl group, pyrrolidinylcarbonyl group, 3-hydroxy Pyrrolidinylcarbonyl group, 3-fluoropyrrolidinylcarbonyl group, piperidinylcarbonyl group, piperazinylcarbonyl group, morpholinylcarbonyl group, tetrahydropyranylcarbonyl , Pyridylcarbonyl group, furoyl group, a thiophene group and the like.

Among these substituents represented by R ¹ and R ^2, they have a hydrogen atom, an alkyl group, an acyl group, an alkoxy group, an alkoxyalkyl group, a hydroxyalkyl group, an alkoxycarbonyl group, an alkoxycarbonylalkyl group, and a substituent. Acylamino group, acylaminoalkyl group, N, N-dialkylaminoalkyl group, N-alkyl-N-alkoxycarbamoyl group, carbazoyl group optionally having 1 to 3 alkyl groups, alkylsulfonyl group, alkoxy A carbonylamino group, a carbamoyl group, an N-alkylcarbamoyl group which may have a substituent on the alkyl group, an N, N-dialkylcarbamoyl group which may have a substituent on the alkyl group, an alkylsulfonylamino group, 3-6 membered optionally having an alkoxycarbonylacyl group and a substituent A heterocyclic carbonyl group is preferred.

R ¹ and R ² are preferably the case where R ¹ is a hydrogen atom, and R ² is a substituent listed as the above preferred group.
Examples of preferable specific substituents for R ¹ and R ² include hydrogen atom, methyl group, ethyl group, isopropyl group, acetyl group, propionyl group, methoxy group, ethoxy group, methoxymethyl group, methoxyethyl group, hydroxy group. Methyl group, 2-hydroxyethyl group, 1-hydroxy-1-methylethyl group, methoxycarbonyl group, ethoxycarbonyl group, acetylamino group, methoxyacetylamino group, acetylaminomethyl group, acetylaminoethyl group, N, N- Dimethylaminomethyl group, N, N-dimethylaminoethyl group, N, N-diethylaminomethyl group, N-methoxy-N-methylcarbamoyl group, N, N-dimethylcarbazoyl group, N, N, N′-trimethylcarba Zoyl group, methanesulfonyl group, methoxycarbonylamino group, ethoxycal Nylamino group, carbamoyl group, N-methylcarbamoyl group, N-ethylcarbamoyl group, N-propylcarbamoyl group, N-isopropylcarbamoyl group, N-tert-butylcarbamoyl group, N-cyclopropylcarbamoyl group, N-cyclopropylmethyl Carbamoyl group, N- (1-ethoxycarbonylcyclopropyl) carbamoyl group, N- (2-hydroxyethyl) carbamoyl group, N- (2-fluoroethyl) carbamoyl group, N- (2-methoxyethyl) carbamoyl group, N -(Carboxymethyl) carbamoyl group, N- (2-aminoethyl) carbamoyl group, N- (2-amidinoethyl) carbamoyl group, N, N-dimethylcarbamoyl group, N, N-diethylcarbamoyl group, N-ethyl- N-methylcarbamoyl group, N -Isopropyl-N-methylcarbamoyl group, N-methyl-N-propylcarbamoyl group, N- (2-hydroxyethyl) -N-methylcarbamoyl group, N- (2-fluoroethyl) -N-methylcarbamoyl group, N , N-bis (2-hydroxyethyl) carbamoyl group, N, N-bis (2-fluoroethyl) carbamoyl group, N- (2-methoxyethyl) -N-methylcarbamoyl group, N-carboxymethyl-N-methyl Carbamoyl group, N, N-bis (2-aminoethyl) carbamoyl group, methylsulfonylamino group, ethylsulfonylamino group, methoxyacetyl group, azetidinocarbonyl group, 3-methoxyazetidinocarbonyl group, 3-hydroxyazetidinocarbonyl Group, pyrrolidinocarbonyl group, 3-hydroxypyrrolidinocar Nyl group, 3-fluoropyrrolidinocarbonyl group, 3,4-dimethoxypyrrolidinocarbonyl group, piperidinocarbonyl group, piperazinocarbonyl group, morpholinocarbonyl group, (tetrahydropyran-4-yl) carbonyl group, etc. It is done.

As described above, R ¹ and R ² are preferably a case where R ¹ is a hydrogen atom, and R ² is the above-described specific substituent or the like. A good N, N-dialkylcarbamoyl group is preferable, and among them, a case of N, N-dimethylcarbamoyl group is preferable.

Q ³ includes a carbonyl group, —C (═O) —C (═O) —NH—, —C (═S) —C (═O) —NH—, —C (═O) —C (= S) -NH- and -C (= S) -C (= S) -NH- are preferred.

As the substituent for Q ⁴ , a halogen atom, an alkyl group, an alkenyl group, an alkynyl group, a hydroxyalkyl group, an alkoxy group, an alkoxyalkyl group, a carboxyalkyl group, an acyl group, an N-alkylcarbamoyl group, an N, N-dialkylcarbamoyl group Groups, alkoxycarbonyl groups, alkoxycarbonylalkyl groups and halogenoalkyl groups. The halogen atom represents a fluorine atom, a chlorine atom, a bromine atom or an iodine atom, the alkyl group represents a linear, branched or cyclic C _{1 to} C ₆ alkenyl group represents a linear or branched group. or shows what the C ₂ -C ₆ cyclic alkynyl group designates those C ₁ -C ₆ linear or branched, hydroxyl 1 hydroxyalkyl group in C ₁ -C ₆ alkyl group as described above An alkoxy group represents a linear, branched or cyclic C _{1 to} C ₆ , and an alkoxyalkyl group represents the above C _{1 to} C ₆ alkyl group to the above C ₁ to C _6. 1 C ₆ alkoxy group represents those substituted carboxyalkyl group indicates that one carboxyl group in C ₁ -C ₆ alkyl group described above is substituted, the acyl group is an alkanoyl group of C ₁ -C ₆ ( Allyl such as benzoyl and naphthoyl groups) Group, or indicates a C ₁ -C ₆ alkanoyl group to said C ₆ -C ₁₄ aryl alkanoyl radicals in which an aryl group is substituted the, N- alkylcarbamoyl group, C ₁ -C ₆ alkyl group described above nitrogen A carbamoyl group substituted on an atom, an N, N-dialkylcarbamoyl group represents a carbamoyl group in which the above C ₁ -C ₆ alkyl group is substituted on a nitrogen atom, and an alkoxycarbonyl group represents the above C ₁ ~ C ₆ alkoxy group and a carbonyl group, an alkoxycarbonylalkyl group is a C ₁ -C ₆ alkyl group substituted with one of the above C ₁ -C ₆ alkoxycarbonyl groups, halogeno The alkyl group is a group in which 1 to 3 halogen atoms are substituted on the above C ₁ -C ₆ alkyl group.

  Among the above substituents, a hydrogen atom, a cyano group, a halogen atom, an alkyl group, an alkenyl group, an alkynyl group and a halogenoalkyl group are preferable, and a halogen atom, an alkyl group and an alkynyl group are particularly preferable. In this case, the halogen atom is preferably a fluorine atom, a chlorine atom or a bromine atom, the alkyl group is preferably a methyl group, and the alkynyl group is preferably an ethynyl group.

Hereinafter, an example of preferred substituents of Q ^4.
Examples of the phenyl group that may have one or two substituents include 4-chlorophenyl group, 4-fluorophenyl group, 4-bromophenyl group, 4-ethynylphenyl group, 3-chlorophenyl group, and 3-fluorophenyl group. 3-bromophenyl group, 3-ethynylphenyl group, 3-chloro-4-fluorophenyl group, 4-chloro-3-fluorophenyl group, 4-chloro-2-fluorophenyl group, 2-chloro-4-fluoro Phenyl group, 4-bromo-2-fluorophenyl group, 2-bromo-4-fluorophenyl group, 2,4-dichlorophenyl group, 2,4-difluorophenyl group, 2,4-dibromophenyl group, 4-chloro- 3-methylphenyl group, 4-fluoro-3-methylphenyl group, 4-bromo-3-methylphenyl group, 4-chloro-2-methyl Eniru group, 4-fluoro-2-methylphenyl group, 4-bromo-2-methylphenyl group, 3,4-dichlorophenyl group, 3,4-difluorophenyl group, etc. 3,4-dibromophenyl group.

  Examples of the naphthyl group which may have 1 to 2 substituents include 6-chloro-2-naphthyl group, 6-fluoro-2-naphthyl group, 6-bromo-2-naphthyl group, 6-ethynyl-2- Examples include naphthyl group, 7-chloro-2-naphthyl group, 7-fluoro-2-naphthyl group, 7-bromo-2-naphthyl group, 7-ethynyl-2-naphthyl group and the like.

  Examples of the pyridyl group that may have 1 to 2 substituents include 2-pyridyl group, 3-pyridyl group, 4-pyridyl group, 4-chloro-2-pyridyl group, 4-fluoro-2-pyridyl group, 4-bromo-2-pyridyl group, 4-ethynyl-2-pyridyl group, 4-chloro-3-pyridyl group, 4-fluoro-3-pyridyl group, 4-bromo-3-pyridyl group, 4-ethynyl-3 -Pyridyl group, 5-chloro-2-pyridyl group, 5-fluoro-2-pyridyl group, 5-bromo-2-pyridyl group, 5-ethynyl-2-pyridyl group, 4-chloro-5-fluoro-2- Pyridyl group, 5-chloro-4-fluoro-2-pyridyl group, 5-chloro-3-pyridyl group, 5-fluoro-3-pyridyl group, 5-bromo-3-pyridyl group, 5-ethynyl-3-pyridyl Group is a preferred example In particular, 2-pyridyl group, 3-pyridyl group, 4-pyridyl group, 4-chloro-2-pyridyl group, 4-fluoro-2-pyridyl group, 4-bromo-2-pyridyl group, 4-ethynyl 2-pyridyl group, 4-chloro-3-pyridyl group, 4-fluoro-3-pyridyl group, 4-bromo-3-pyridyl group, 4-ethynyl-3-pyridyl group, 5-chloro-2-pyridyl group 5-fluoro-2-pyridyl group, 5-bromo-2-pyridyl group, 5-ethynyl-2-pyridyl group, 4-chloro-5-fluoro-2-pyridyl group, 5-chloro-4-fluoro-2 -Pyridyl group, 5-chloro-3-pyridyl group, 5-fluoro-3-pyridyl group, 5-bromo-3-pyridyl group and 5-ethynyl-3-pyridyl group are preferred, among which 2-pyridyl group, 3 -Pyridyl group, 4 Pyridyl group, 5-chloro-2-pyridyl group, 5-fluoro-2-pyridyl group, 5-bromo-2-pyridyl group, 5-ethynyl-2-pyridyl group, 5-chloro-4-fluoro-2-pyridyl group And more preferably a 4-chloro-5-fluoro-2-pyridyl group.

  Examples of the pyrimidinyl group which may have 1 to 2 substituents include 5-chloro-2-pyrimidyl group, 5-fluoro-2-pyrimidyl group, 5-bromo-2-pyrimidyl group, 5-ethynyl-2- Examples include a pyrimidyl group.

  Examples of the pyridazinyl group which may have 1 to 2 substituents include 4-chloro-3-pyridazinyl group, 4-fluoro-3-pyridazinyl group, 4-bromo-3-pyridazinyl group, 4-ethynyl-3- Preferred examples include pyridazinyl group, 6-chloro-3-pyridazinyl group, 6-fluoro-3-pyridazinyl group, 6-bromo-3-pyridazinyl group, 6-ethynyl-3-pyridazinyl group and the like. A chloro-3-pyridazinyl group, a 6-fluoro-3-pyridazinyl group, a 6-bromo-3-pyridazinyl group, and a 6-ethynyl-3-pyridazinyl group are preferable. Among them, a 4-chloro-3-pyridazinyl group, 4-fluoro A -3-pyridazinyl group, a 4-bromo-3-pyridazinyl group, and a 4-ethynyl-3-pyridazinyl group are more preferable.

  Examples of the indolyl group having 1 to 2 substituents include 5-chloroindolyl group, 5-fluoroindolyl group, 5-bromoindolyl group, 5-ethynylindolyl group, and 5-methylindolyl group. Group, 5-chloro-4-fluoroindolyl group, 5-chloro-3-fluoroindolyl group, 5-fluoro-3-chloroindolyl group, 5-ethynyl-3-fluoroindolyl group, 5-chloro- 3- (N, N-dimethylcarbamoyl) indolyl group, 5-fluoro-3- (N, N-dimethylcarbamoyl) indolyl group, 5-chloro-3-formylimidyl group, 5-fluoro-3-formylindolyl Group, 6-chloroindolyl group, 6-fluoroindolyl group, 6-bromoindolyl group, 6-ethynylindolyl group, 6-methylindolyl group, etc. As examples, 5-chloroindol-2-yl group, 5-fluoroindol-2-yl group, 5-bromoindol-2-yl group, 5-ethynylindol-2-yl group, Methylindol-2-yl group, 5-chloro-4-fluoroindol-2-yl group, 5-chloro-3-fluoroindol-2-yl group, 3-bromo-5-chloroindol-2-yl group, 3-chloro-5-fluoroindol-2-yl group, 3-bromo-5-fluoroindol-2-yl group, 5-bromo-3-chloroindol-2-yl group, 5-bromo-3-fluoroindole 2-yl group, 5-chloro-3-formylindol-2-yl group, 5-fluoro-3-formylindol-2-yl group, 5-bromo-3-formylindole 2-yl group, 5-ethynyl-3-formylindol-2-yl group, 5-chloro-3- (N, N-dimethylcarbamoyl) indol-2-yl group, 5-fluoro-3- (N, N-dimethylcarbamoyl) indol-2-yl group, 5-bromo-3- (N, N-dimethylcarbamoyl) indol-2-yl group, 5-ethynyl-3- (N, N-dimethylcarbamoyl) indole-2 -Yl group, 6-chloroindol-2-yl group, 6-fluoroindol-2-yl group, 6-bromoindol-2-yl group, 6-ethynylindol-2-yl group, 6-methylindole-2 -Yl group, 5-chloroindol-3-yl group, 5-fluoroindol-3-yl group, 5-bromoindol-3-yl group, 5-ethynylindol-3-yl Group, 5-methylindol-3-yl group, 5-chloro-4-fluoroindol-3-yl group, 6-chloroindol-3-yl group, 6-fluoroindol-3-yl group, 6-bromoindole -3-yl group, 6-ethynylindol-3-yl group, 6-methylindol-3-yl group and the like are preferable, among which 5-chloroindol-2-yl group and 5-fluoroindol-2-yl group 5-bromoindol-2-yl group, 5-ethynylindol-2-yl group, 5-methylindol-2-yl group, 5-chloro-4-fluoroindol-2-yl group, 6-chloroindole- 2-yl group, 6-fluoroindol-2-yl group, 6-bromoindol-2-yl group, 6-ethynylindol-2-yl group, 6-methylindole-2 Yl group, 5-chloro-3-fluoroindol-2-yl group, 3-bromo-5-chloroindol-2-yl group, 3-chloro-5-fluoroindol-2-yl group, 3-bromo-5 -Fluoroindol-2-yl group, 5-bromo-3-chloroindol-2-yl group, 5-bromo-3-fluoroindol-2-yl group, 5-chloro-3-formylindol-2-yl group 5-fluoro-3-formylindol-2-yl group, 5-bromo-3-formylindol-2-yl group, 5-ethynyl-3-formylindol-2-yl group, 5-chloro-3- ( N, N-dimethylcarbamoyl) indol-2-yl group, 5-fluoro-3- (N, N-dimethylcarbamoyl) indol-2-yl group, 5-bromo-3- (N, N-dimethyl) Carbamoyl) indol-2-yl group, 5-ethynyl-3-(N, is N- dimethylcarbamoyl) indol-2-yl group further preferred.

  Examples of the benzothienyl group which may have 1 to 2 substituents include 5-chlorobenzothienyl group, 5-fluorobenzothienyl group, 5-bromobenzothienyl group, 5-ethynylbenzothienyl group, 5-methylbenzo Thienyl group, 5-chloro-4-fluorobenzothienyl group, 6-chlorobenzothienyl group, 6-fluorobenzothienyl group, 6-bromobenzothienyl group, 6-ethynylbenzothienyl group, 6-methylbenzothienyl group etc. Preferred examples include 5-chlorobenzothiophen-2-yl group, 5-fluorobenzothiophen-2-yl group, 5-bromobenzothiophen-2-yl group, and 5-ethynylbenzothiophen-2-yl group. Group, 5-methylbenzothiophen-2-yl group, 5-chloro-4-fluorobenzothiophene 2-yl group, 6-chlorobenzothiophen-2-yl group, 6-fluorobenzothiophen-2-yl group, 6-bromobenzothiophen-2-yl group, 6-ethynylbenzothiophen-2-yl group, 6-methylbenzothiophen-2-yl group, 5-chlorobenzothiophen-3-yl group, 5-fluorobenzothiophen-3-yl group, 5-bromobenzothiophen-3-yl group, 5-ethynylbenzothiophene- 3-yl group, 5-methylbenzothiophen-3-yl group, 5-chloro-4-fluorobenzothiophen-3-yl group, 6-chlorobenzothiophen-3-yl group, 6-fluorobenzothiophene-3- Yl group, 6-bromobenzothiophen-3-yl group, 6-ethynylbenzothiophen-3-yl group, 6-methylbenzothiophene -3-yl group and the like are preferable, and 5-chlorobenzothiophen-2-yl group, 5-fluorobenzothiophen-2-yl group, among them, 5-bromobenzothiophen-2-yl group, 5-ethynylbenzothiophene- 2-yl group, 5-methylbenzothiophen-2-yl group, 5-chloro-4-fluorobenzothiophen-2-yl group, 6-chlorobenzothiophen-2-yl group, 6-fluorobenzothiophen-2-yl An yl group, a 6-bromobenzothiophen-2-yl group, a 6-ethynylbenzothiophen-2-yl group, and a 6-methylbenzothiophen-2-yl group are more preferable.

  Examples of the benzofuranyl group which may have 1 to 2 substituents include 5-chlorobenzofuranyl group, 5-fluorobenzofuranyl group, 5-bromobenzofuranyl group, 5-ethynylbenzofuranyl group, 5 -Methylbenzofuranyl group, 5-chloro-4-fluorobenzofuranyl group, 6-chlorobenzofuranyl group, 6-fluorobenzofuranyl group, 6-bromobenzofuranyl group, 6-ethynylbenzofuranyl group , 6-methylbenzofuranyl group and the like are preferable examples. Particularly, 5-chlorobenzofuran-2-yl group, 5-fluorobenzofuran-2-yl group, 5-bromobenzofuran-2-yl group, 5- Ethynylbenzofuran-2-yl group, 5-methylbenzofuran-2-yl group, 5-chloro-4-fluorobenzofuran-2-yl group, 6-chloro Benzofuran-2-yl group, 6-fluorobenzofuran-2-yl group, 6-bromobenzofuran-2-yl group, 6-ethynylbenzofuran-2-yl group, 6-methylbenzofuran-2-yl group, 5-chloro Benzofuran-3-yl group, 5-fluorobenzofuran-3-yl group, 5-bromobenzofuran-3-yl group, 5-ethynylbenzofuran-3-yl group, 5-methylbenzofuran-3-yl group, 5-chloro -4-fluorobenzofuran-3-yl group, 6-chlorobenzofuran-3-yl group, 6-fluorobenzofuran-3-yl group, 6-bromobenzofuran-3-yl group, 6-ethynylbenzofuran-3-yl group , 6-methylbenzofuran-3-yl group and the like are preferable, among which 5-chlorobenzofuran-2-yl group, 5-fluoroben Furan-2-yl group, 5-bromobenzofuran-2-yl group, 5-ethynylbenzofuran-2-yl group, 5-methylbenzofuran-2-yl group, 5-chloro-4-fluorobenzofuran-2-yl group 6-chlorobenzofuran-2-yl group, 6-fluorobenzofuran-2-yl group, 6-bromobenzofuran-2-yl group, 6-ethynylbenzofuran-2-yl group, 6-methylbenzofuran-2-yl group Is more preferable.

  Examples of the benzoimidazolyl group which may have 1 to 2 substituents include 5-chlorobenzimidazolyl group, 5-fluorobenzoimidazolyl group, 5-bromobenzoimidazolyl group, 5-ethynylbenzimidazolyl group, 6-chlorobenzimidazolyl group, 6-fluoro Benzimidazolyl group, 6-bromobenzoimidazolyl group, 6-ethynylbenzimidazolyl group and the like are preferable examples, and in particular, 5-chlorobenzimidazol-2-yl group, 5-fluorobenzimidazol-2-yl group, 5-bromobenzo Imidazol-2-yl group, 5-ethynylbenzimidazol-2-yl group, 6-chlorobenzimidazol-2-yl group, 6-fluorobenzoimidazol-2-yl group, 6-bromobenzoimidazol-2-yl group , 6- Tinylbenzimidazol-2-yl group is more preferable, 5-chlorobenzimidazol-2-yl group, 5-fluorobenzoimidazol-2-yl group, 5-bromobenzoimidazol-2-yl group, 5-ethynylbenzo Imidazol-2-yl group, 6-chlorobenzimidazol-2-yl group, 6-fluorobenzoimidazol-2-yl group, 6-bromobenzoimidazol-2-yl group, 6-ethynylbenzimidazol-2-yl group Are particularly preferred. Among them, a 5-chlorobenzoimidazol-2-yl group, a 5-fluorobenzimidazol-2-yl group, a 5-bromobenzoimidazol-2-yl group, and a 5-ethynylbenzimidazol-2-yl group are preferable. Further preferred.

  Preferred examples of the quinolyl group having 1 to 2 substituents include 6-chloroquinolinyl group, 6-fluoroquinolinyl group, 6-bromoquinolinyl group, 6-ethynylquinolinyl group and the like. In particular, 6-chloroquinolin-2-yl group, 6-fluoroquinolin-2-yl group, 6-bromoquinolin-2-yl group, 6-ethynylquinolin-2-yl group, 6-chloroquinolin-3-yl Group, 6-fluoroquinolin-3-yl group, 6-bromoquinolin-3-yl group, 6-ethynylquinolin-3-yl group, 7-chloroquinolin-2-yl group, 7-fluoroquinolin-2-yl Group, 7-bromoquinolin-2-yl group, 7-ethynylquinolin-2-yl group, 7-chloroquinolin-3-yl group, 7-fluoroquinolin-3-yl group, 7-bromoquinoli -3-yl group, 7-ethynylquinolin-3-yl group and the like are preferable, among which 6-chloroquinolin-2-yl group, 6-fluoroquinolin-2-yl group, 6-bromoquinolin-2-yl group 6-ethynylquinolin-2-yl group, 7-chloroquinolin-3-yl group, 7-fluoroquinolin-3-yl group, 7-bromoquinolin-3-yl group, 7-ethynylquinolin-3-yl group Among these, it is more preferable.

  Examples of the isoquinolyl group which may have 1 to 2 substituents include 6-chloroisoquinolinyl group, 6-fluoroisoquinolinyl group, 6-bromoisoquinolinyl group, 6-ethynylisoquinolyl group. Nyl group and the like are preferable examples. Particularly, 6-chloroisoquinolin-3-yl group, 6-fluoroisoquinolin-3-yl group, 6-bromoisoquinolin-3-yl group, 6-ethynylisoquinolin-3-yl Group, 7-chloroisoquinolin-3-yl group, 7-fluoroisoquinolin-3-yl group, 7-bromoisoquinolin-3-yl group, 7-ethynylisoquinolin-3-yl group and the like are preferable. Isoquinolin-3-yl group, 7-fluoroisoquinolin-3-yl group, 7-bromoisoquinolin-3-yl group, 7-ethynylisoquinolin-3-yl Group are more preferred.

  Examples of the cinnolyl group which may have 1 to 2 substituents include 7-chlorocinnolinyl group, 7-fluorocinnolinyl group, 7-bromocinnolinyl group, 7-ethynylcinnolinyl group and the like. Preferred examples include 7-chlorocinnolin-3-yl group, 7-fluorocinnolin-3-yl group, 7-bromocinnolin-3-yl group, 7-ethynylcinnolin-3-yl. Group is preferred, among which 7-chlorocinnolin-3-yl group, 7-fluorocinnolin-3-yl group, 7-bromocinnolin-3-yl group, 7-ethynylcinnolin-3-yl group Is more preferable.

  Examples of the thienyl group which may have 1 to 2 substituents include 4-chloro-2-thienyl group, 4-fluoro-2-thienyl group, 4-bromo-2-thienyl group, 4-ethynyl-2- Examples include thienyl group, 5-chloro-2-thienyl group, 5-fluoro-2-thienyl group, 5-bromo-2-thienyl group, 5-ethynyl-2-thienyl group and the like.

  Examples of the thiazolyl group which may have 1 to 2 substituents include 5-chloro-2-thiazolyl group, 5-fluoro-2-thiazolyl group, 5-bromo-2-thiazolyl group, 5-ethynyl-2- Examples include a thiazolyl group, and a 5-chloro-2-thiazolyl group, a 5-fluoro-2-thiazolyl group, a 5-bromo-2-thiazolyl group, and a 5-ethynyl-2-thiazolyl group are particularly preferable.

  Examples of the oxazolyl group which may have 1 to 2 substituents include 5-chloro-2-oxazolyl group, 5-fluoro-2-oxazolyl group, 5-bromo-2-oxazolyl group, 5-ethynyl-2- An oxazolyl group etc. are mentioned.

  Preferred examples of the styryl group that may have 1 to 2 substituents include a chlorostyryl group, a fluorostyryl group, a bromostyryl group, an ethynylstyryl group, and the like. Particularly, a 4-chlorostyryl group, 4- A fluorostyryl group, 4-bromostyryl group, 4-ethynylstyryl group and the like are preferable.

The compound represented by the general formula (1) may be a hydrate or a solvate, or may be a pharmaceutically acceptable salt, a hydrate of a salt, or a solvate.
Salts include hydrochloride, sulfate, hydrobromide, hydroiodide, phosphate, nitrate, benzoate, methanesulfonate, 2-hydroxyethanesulfonate, p-toluenesulfonate , Acetate, propanoate, oxalate, malonate, succinate, glutarate, adipate, tartrate, maleate, fumarate, malate, mandelate, etc. , Hydrochloride, methanesulfonate, and p-toluenesulfonate are preferable, and hydrochloride is particularly preferable.

As a particularly preferred compound represented by the general formula (1), N-{(1R, 2S, 5S) -2-{[(5-chloroindol-2-yl) carbonyl] amino} -5-[(dimethyl) Amino) carbonyl] cyclohexyl} -5-methyl-4,5,6,7-tetrahydrothiazolo [5,4-c] pyridine-2-carboxamide hydrochloride,
N-((1R, 2S, 5S) -2-{[(5-chloroindol-2-yl) carbonyl] amino} -5-{[(3S) -3-fluoropyrrolidinyl] carbonyl} cyclohexyl)- 5-methyl-4,5,6,7-tetrahydrothiazolo [5,4-c] pyridine-2-carboxamide hydrochloride,
N-((1R, 2S, 5S) -2-{[(5-chloroindol-2-yl) carbonyl] amino} -5-{[methoxy (methyl) amino] carbonyl} cyclohexyl) -5-methyl-4 , 5,6,7-tetrahydrothiazolo [5,4-c] pyridine-2-carboxamide hydrochloride,
N-{(1R, 2S, 5S) -2-{[(5-chloroindol-2-yl) carbonyl] amino} -5-[(2,2-dimethylhydrazino) carbonyl] cyclohexyl} -5-methyl -4,5,6,7-tetrahydrothiazolo [5,4-c] pyridine-2-carboxamide hydrochloride,
6-chloro-N-((1S, 2R, 4S) -4-[(dimethylamino) carbonyl] -2-{[(5-methyl-4,5,6,7-tetrahydrothiazolo [5,4- c] pyridin-2-yl) carbonyl] amino} cyclohexyl) -2-quinolinecarboxamide hydrochloride,

N ^1- (4-chlorophenyl) -N ² -((1S, 2R, 4S) -4-[(dimethylamino) carbonyl] -2-{[(5-methyl-4,5,6,7-tetrahydrothia Zolo [5,4-c] pyridin-2-yl) carbonyl] amino} cyclohexyl) ethanediamide hydrochloride,
N ^1- (5-chloropyridin-2-yl) -N ² -((1S, 2R, 4S) -4-[(dimethylamino) carbonyl] -2-{[(5-methyl-4,5,6 , 7-tetrahydrothiazolo [5,4-c] pyridin-2-yl) carbonyl] amino} cyclohexyl) ethanediamide hydrochloride,
N ¹ - (3- ^{chlorophenyl) -N 2 - ((1S,} 2R, 4S) -4 - [( dimethylamino) carbonyl] -2 - {[(5-methyl-4,5,6,7-tetrahydrothiazolo Zolo [5,4-c] pyridin-2-yl) carbonyl] amino} cyclohexyl) ethanediamide hydrochloride,
N ¹ -((1S, 2R, 4S) -4-[(dimethylamino) carbonyl] -2-{[(5-methyl-4,5,6,7-tetrahydrothiazolo [5,4-c] pyridine -2-yl) carbonyl] amino} cyclohexyl) -N ^2- (4-fluorophenyl) ethanediamide hydrochloride,
N ^1- (4-Bromophenyl) -N ² -((1S, 2R, 4S) -4-[(dimethylamino) carbonyl] -2-{[(5-methyl-4,5,6,7-tetrahydro Thiazolo [5,4-c] pyridin-2-yl) carbonyl] amino} cyclohexyl) ethanediamide hydrochloride,

N ^1- (4-Chloro-2-methylphenyl) -N ² -((1S, 2R, 4S) -4-[(dimethylamino) carbonyl] -2-{[(5-methyl-4,5,6 , 7-tetrahydrothiazolo [5,4-c] pyridin-2-yl) carbonyl] amino} cyclohexyl) ethanediamide hydrochloride,
N ^1- (4-Chloro-3-methylphenyl) -N ² -((1S, 2R, 4S) -4-[(dimethylamino) carbonyl] -2-{[(5-methyl-4,5,6 , 7-tetrahydrothiazolo [5,4-c] pyridin-2-yl) carbonyl] amino} cyclohexyl) ethanediamide hydrochloride,
N ^1- (4-Chloro-2-fluorophenyl) -N ² -((1S, 2R, 4S) -4-[(dimethylamino) carbonyl] -2-{[(5-methyl-4,5,6 , 7-tetrahydrothiazolo [5,4-c] pyridin-2-yl) carbonyl] amino} cyclohexyl) ethanediamide hydrochloride,
N ^1- (2,4-dichlorophenyl) -N ² -((1S, 2R, 4S) -4-[(dimethylamino) carbonyl] -2-{[(5-methyl-4,5,6,7- Tetrahydrothiazolo [5,4-c] pyridin-2-yl) carbonyl] amino} cyclohexyl) ethanediamide hydrochloride,
N ^1- (3,4-dichlorophenyl) -N ² -((1S, 2R, 4S) -4-[(dimethylamino) carbonyl] -2-{[(5-methyl-4,5,6,7- Tetrahydrothiazolo [5,4-c] pyridin-2-yl) carbonyl] amino} cyclohexyl) ethanediamide,

N ^1- (2,4-difluorophenyl) -N ² -((1S, 2R, 4S) -4-[(dimethylamino) carbonyl] -2-{[(5-methyl-4,5,6,7 -Tetrahydrothiazolo [5,4-c] pyridin-2-yl) carbonyl] amino} cyclohexyl) ethanediamide hydrochloride,
N ^1- (3,4-difluorophenyl) -N ² -((1S, 2R, 4S) -4-[(dimethylamino) carbonyl] -2-{[(5-methyl-4,5,6,7 -Tetrahydrothiazolo [5,4-c] pyridin-2-yl) carbonyl] amino} cyclohexyl) ethanediamide,
N ¹ -((1S, 2R, 4S) -4-[(dimethylamino) carbonyl] -2-{[(5-methyl-4,5,6,7-tetrahydrothiazolo [5,4-c] pyridine -2-yl) carbonyl] amino} cyclohexyl) -N ^2- (pyridin-4-yl) ethanediamide hydrochloride,
N ^1- (5-Bromopyridin-2-yl) -N ² -((1S, 2R, 4S) -4-[(dimethylamino) carbonyl] -2-{[(5-methyl-4,5,6 , 7-tetrahydrothiazolo [5,4-c] pyridin-2-yl) carbonyl] amino} cyclohexyl) ethanediamide hydrochloride,
N ¹ - (6- ^{chloropyridin-3-yl) -N 2 - ((1S,} 2R, 4S) -4 - [( dimethylamino) carbonyl] -2 - {[(5-methyl -4,5,6 , 7-tetrahydrothiazolo [5,4-c] pyridin-2-yl) carbonyl] amino} cyclohexyl) ethanediamide hydrochloride,

N ¹ - (6- ^{chloro-3-yl) -N 2 - ((1S,} 2R, 4S) -4 - [( dimethylamino) carbonyl] -2 - {[(5-methyl -4,5,6 , 7-tetrahydrothiazolo [5,4-c] pyridin-2-yl) carbonyl] amino} cyclohexyl) ethanediamide hydrochloride,
N ^1- (5-chlorothiazol-2-yl) -N ² -((1S, 2R, 4S) -4-[(dimethylamino) carbonyl] -2-{[(5-methyl-4,5,6 , 7-tetrahydrothiazolo [5,4-c] pyridin-2-yl) carbonyl] amino} cyclohexyl) ethanediamide hydrochloride,
N ^1- (5-chloropyridin-2-yl) -N ² -((1S, 2R, 4S) -4-[(dimethylamino) carbonyl] -2-{[(5-methyl-5,6-dihydro -4H-pyrrolo [3,4-d] thiazol-2-yl) carbonyl] amino} cyclohexyl) ethanediamide hydrochloride,
N-{(1R, 2S, 5S) -2-{[2- (4-chloroanilino) -2-oxoethanethioyl] amino} -5-[(dimethylamino) carbonyl] cyclohexyl} -5-methyl-4 , 5,6,7-tetrahydrothiazolo [5,4-c] pyridine-2-carboxamide,
N-{(1R, 2S, 5S) -2-({2-[(5-chloropyridin-2-yl) amino] -2-oxoethanethiol} amino) -5-[(dimethylamino) carbonyl] Cyclohexyl} -5-methyl-4,5,6,7-tetrahydrothiazolo [5,4-c] pyridine-2-carboxamide,

N-{(1R, 2S, 5S) -2-({2-[(5-chloropyridin-2-yl) amino] -2-thioxoacetyl} amino) -5-[(dimethylamino) carbonyl] cyclohexyl } -5-methyl-4,5,6,7-tetrahydrothiazolo [5,4-c] pyridine-2-carboxamide,
N ^1- (5-chloro-2-thienyl) -N ² -((1S, 2R, 4S) -4-[(dimethylamino) carbonyl] -2-{[(5-methyl-4,5,6, 7-tetrahydrothiazolo [5,4-c] pyridin-2-yl) carbonyl] amino} cyclohexyl) ethanediamide hydrochloride,
N-{(1R, 2S, 5S) -2-{[(4-chloroanilino) carbonyl] amino} -5-[(dimethylamino) carbonyl] -cyclohexyl} -5-methyl-4,5,6,7- Tetrahydrothiazolo [5,4-c] pyridine-2-carboxamide hydrochloride,
N ¹ -((1S, 2R, 4S) -4-[(dimethylamino) carbonyl] -2-{[(5-methyl-4,5,6,7-tetrahydrothiazolo [5,4-c] pyridine 2-yl) carbonyl] amino} cyclohexyl) -N ² - (5-fluoropyridin-2-yl) ethanediamide hydrochloride,
N ^1- (4-chlorophenyl) -N ² -((1S, 2R, 4S) -4-[(dimethylamino) carbonyl] -2-{[(5-methyl-5,6-dihydro-4H-pyrrolo [ 3,4-d] thiazol-2-yl) carbonyl] amino} cyclohexyl) ethanediamide hydrochloride,

N ¹ - [4-chloro-2- (trifluoromethyl) ^{phenyl] -N 2 - ((1S,} 2R, 4S) -4 - [( dimethylamino) carbonyl] -2 - {[(5-methyl-4 , 5,6,7-tetrahydrothiazolo [5,4-c] pyridin-2-yl) carbonyl] amino} cyclohexyl) ethanediamide hydrochloride,
N ^1- {4-chloro-2-[(dimethylamino) carbonyl] phenyl} -N ² -((1S, 2R, 4S) -4-[(dimethylamino) carbonyl] -2-{[(5-methyl -4,5,6,7-tetrahydrothiazolo [5,4-c] pyridin-2-yl) carbonyl] amino} cyclohexyl) ethanediamide hydrochloride,
N ^1- [4-Chloro-2- (hydroxymethyl) phenyl] -N ² -((1S, 2R, 4S) -4-[(dimethylamino) carbonyl] -2-{[(5-methyl-4, 5,6,7-tetrahydrothiazolo [5,4-c] pyridin-2-yl) carbonyl] amino} cyclohexyl) ethanediamide hydrochloride,
N ^1- (4-Chloro-2-methoxyphenyl) -N ² -((1S, 2R, 4S) -4-[(dimethylamino) carbonyl] -2-{[(5-methyl-4,5,6 , 7-tetrahydrothiazolo [5,4-c] pyridin-2-yl) carbonyl] amino} cyclohexyl) ethanediamide hydrochloride,
N ^1- (4-chlorophenyl) -N ² -((3R, 4S) -1- (2-methoxyacetyl) -3-{[(5-methyl-4,5,6,7-tetrahydrothiazolo [5 , 4-c] pyridin-2-yl) carbonyl] amino} piperidin-4-yl) ethanediamide hydrochloride,

N ^1- (5-chloropyridin-2-yl) -N ² -((3R, 4S) -1- (2-methoxyacetyl) -3-{[(5-methyl-4,5,6,7- Tetrahydrothiazolo [5,4-c] pyridin-2-yl) carbonyl] amino} piperidin-4-yl) ethanediamide hydrochloride,
N ¹ - ^{(5-bromo-2-yl) -N 2 - ((3R,} 4S) -1- (2- methoxyacetyl) -3 - {[(5-methyl-4,5,6,7 Tetrahydrothiazolo [5,4-c] pyridin-2-yl) carbonyl] amino} piperidin-4-yl) ethanediamide hydrochloride,
N ^1- (5-chloropyridin-2-yl) -N ² -((1S, 2R, 4S) -4-{[ethyl (methyl) amino] carbonyl} -2-{[(5-methyl-4, 5,6,7-tetrahydrothiazolo [5,4-c] pyridin-2-yl) carbonyl] amino} cyclohexyl) ethanediamide hydrochloride,
N ^1- (4-Chlorophenyl) -N ² -((1S, 2R, 4S) -4-{[ethyl (methyl) amino] carbonyl} -2-{[(5-methyl-4,5,6,7 -Tetrahydrothiazolo [5,4-c] pyridin-2-yl) carbonyl] amino} cyclohexyl) ethanediamide hydrochloride,
N ¹ - (5-bromo-2-yl) -N ² - ((1S, 2R, 4S) -4 - {[ethyl (methyl) amino] carbonyl} -2 - {[(5-methyl-4, 5,6,7-tetrahydrothiazolo [5,4-c] pyridin-2-yl) carbonyl] amino} cyclohexyl) ethanediamide hydrochloride,

N ^1- (4-Chloro-3-fluorophenyl) -N ² -((1S, 2R, 4S) -4-[(dimethylamino) carbonyl] -2-{[(5-methyl-4,5,6 , 7-tetrahydrothiazolo [5,4-c] pyridin-2-yl) carbonyl] amino} cyclohexyl) ethanediamide hydrochloride,
N ¹ -[(5-chloropyridin-2-yl) amino] -N ² -((1R, 2R, 4S) -4-[(dimethylamino) carbonyl] -2-{[(5-methyl-4, 5,6,7-tetrahydrothiazolo [5,4-c] pyridin-2-yl) carbonyl] amino} cyclohexyl) ethanediamide hydrochloride,
N ^1- (4-chlorophenyl) -N ² -((1R, 2R, 4S) -4-[(dimethylamino) carbonyl] -2-{[(5-methyl-4,5,6,7-tetrahydrothia Zolo [5,4-c] pyridin-2-yl) carbonyl] amino} cyclohexyl) ethanediamide, N ^1- (5-chloropyrimidin-2-yl) -N ² -((1S, 2R, 4S) -4- [(Dimethylamino) carbonyl] -2-{[(5-methyl-4,5,6,7-tetrahydrothiazolo [5,4-c] pyridin-2-yl) carbonyl] amino} cyclohexyl) ethanediamide hydrochloride ,
N ^1- (4-chlorophenyl) -N ² -((1S, 2R, 4S) -4-{[ethyl (methyl) amino] carbonyl} -2-{[(5-methyl-5,6-dihydro-4H -Pyrrolo [3,4-d] thiazol-2-yl) carbonyl] amino} cyclohexyl) ethanediamide hydrochloride,

N ¹ - ^{(5-bromo-2-yl) -N 2 - ((1S,} 2R, 4S) -4 - {[ ethyl (methyl) amino] carbonyl} -2 - {[(5-methyl-5, 6-dihydro-4H-pyrrolo [3,4-d] thiazol-2-yl) carbonyl] amino} cyclohexyl) ethanediamide hydrochloride,
N ¹ - ^{(5-chloropyridin-2-yl) -N 2 - ((1S,} 2R, 4S) -4 - {[ ethyl (methyl) amino] carbonyl} -2 - {[(5-methyl-5, 6-dihydro-4H-pyrrolo [3,4-d] thiazol-2-yl) carbonyl] amino} cyclohexyl) ethanediamide hydrochloride,
N ^1- (4-Chloro-3-methoxyphenyl) -N ² -((1S, 2R, 4S) -4-[(dimethylamino) carbonyl] -2-{[(5-methyl-4,5,6 , 7-tetrahydrothiazolo [5,4-c] pyridin-2-yl) carbonyl] amino} cyclohexyl) ethanediamide hydrochloride,
N ^1- (4-chlorophenyl) -N ² -((1R ^* , 2R ^* )-2-{[(5-methyl-4,5,6,7-tetrahydrothiazolo [5,4-c] pyridine- 2-yl) carbonyl] amino} cyclopentyl) ethanediamide hydrochloride,
N ^1- (5-chloropyridin-2-yl) -N ² -((1R ^* , 2R ^* )-2-{[(5-methyl-4,5,6,7-tetrahydrothiazolo [5,4 -C] pyridin-2-yl) carbonyl] amino} cyclopentyl) ethanediamide hydrochloride,

N ¹ -((1S, 2R, 4S) -4-[(dimethylamino) carbonyl] -2-{[(5-methyl-4,5,6,7-tetrahydrothiazolo [5,4-c] pyridine -2-yl) carbonyl] amino} cyclohexyl) -N ^2- (4-ethynylphenyl) ethanediamide,
N ^1- (5-chloropyrazin-2-yl) -N ² -((1S, 2R, 4S) -4-[(dimethylamino) carbonyl] -2-{[(5-methyl-4,5,6 , 7-tetrahydrothiazolo [5,4-c] pyridin-2-yl) carbonyl] amino} cyclohexyl) ethanediamide hydrochloride,
N ^1- (3-amino-4-chlorophenyl) -N ² -((1S, 2R, 4S) -4-[(dimethylamino) carbonyl] -2-{[(5-methyl-4,5,6, 7-tetrahydrothiazolo [5,4-c] pyridin-2-yl) carbonyl] amino} cyclohexyl) ethanediamide hydrochloride,
N ^1- (2-amino-4-chlorophenyl) -N ² -((1S, 2R, 4S) -4-[(dimethylamino) carbonyl] -2-{[(5-methyl-4,5,6, 7-tetrahydrothiazolo [5,4-c] pyridin-2-yl) carbonyl] amino} cyclohexyl) ethanediamide hydrochloride,
N ¹ - (6- ^{chloro-4-methyl-3-yl) -N 2 - ((1S,} 2R, 4S) -4 - [( dimethylamino) carbonyl] -2 - {[(5-methyl-4 , 5,6,7-tetrahydrothiazolo [5,4-c] pyridin-2-yl) carbonyl] amino} cyclohexyl) ethanediamide hydrochloride,

N ^1- (5-chloropyridin-2-yl) -N ² -((1S, 2R, 4S) -4-[(dimethylamino) carbonyl] -2-{[(4,5,6,7-tetrahydro Thiazolo [5,4-c] pyridin-2-yl) carbonyl] amino} cyclohexyl) ethanediamide hydrochloride,
N ^1- (4-Chloro-3-fluorophenyl) -N ¹ -((3R, 4S) -1- (2-methoxyacetyl) -3-{[(5-methyl-4,5,6,7- Tetrahydrothiazolo [5,4-c] pyridin-2-yl) carbonyl] amino} piperidin-4-yl) ethanediamide hydrochloride,
N ^1- (5-chloro-2-thienyl) -N ² -((3R, 4S) -1- (2-methoxyacetyl) -3-{[(5-methyl-4,5,6,7-tetrahydro Thiazolo [5,4-c] pyridin-2-yl) carbonyl] amino} piperidin-4-yl) ethanediamide hydrochloride,
N ^1- (5-chloropyridin-2-yl) -N ² -((1S, 2R, 4S) -4-[(dimethylamino) carbonyl] -2-{[(5-methyl-4,5,6 , 7-tetrahydrothieno [3,2-c] pyridin-2-yl) carbonyl] amino} cyclohexyl) ethanediamide hydrochloride,
N ^1- (5-chloropyridin-2-yl) -N ² -((1S, 2R, 4S) -4-[(dimethylamino) carbonyl] -2-{[(5-isopropyl-4,5,6 , 7-tetrahydrothiazolo [5,4-c] pyridin-2-yl) carbonyl] amino} cyclohexyl) ethanediamide hydrochloride,

N-((1R, 2S, 5S) -5-[(dimethylamino) carbonyl] -2-{[2- (4-fluoroanilino) -2-oxoethanethioyl] amino} cyclohexyl) -5-methyl -4,5,6,7-tetrahydrothiazolo [5,4-c] pyridine-2-carboxamide hydrochloride,
N-[(1R, 2S, 5S) -5-[(dimethylamino) carbonyl] -2-({2-[(5-fluoropyridin-2-yl) amino] -2-oxoethanethiol} amino) Cyclohexyl] -5-methyl-4,5,6,7-tetrahydrothiazolo [5,4-c] pyridine-2-carboxamide hydrochloride,
N-{(1R, 2S, 5S) -2-({2-[(5-chloropyridin-2-yl) amino] -2-oxoethanethiol} amino) -5-[(dimethylamino) carbonyl] Cyclohexyl} -5-methyl-5H-pyrrolo [3,4-d] thiazole-2-carboxamide,
N-{(1R, 2S, 5S) -2-({2-[(5-chloropyridin-2-yl) amino] -2-oxoethanethiol} amino) -5-[(dimethylamino) carbonyl] Cyclohexyl} -5-methyl-5,6-dihydro-4H-pyrrolo [3,4-d] thiazole-2-carboxamide hydrochloride and the like.

  The antiplatelet drug used in the present invention is selected from aspirin, sarpogrelate, limaprost, cilostazol, a compound represented by general formula (2), and a compound represented by general formula (3).

  The compound represented by the general formula (2) can be produced by the method described in JP-A-63-203684 and JP-A-6-41139 or a method analogous thereto.

  In the general formula (2), the lower alkyl group means a linear, branched, or cyclic alkyl group having 1 to 6 carbon atoms, and includes a lower alkoxycarbonyl group, a lower alkylcarbonyl group, and a lower alkylcarbonyloxy group. The same applies to the lower alkyl group moiety in the group.

R ¹⁰¹ includes a hydrogen atom, methyl group, ethyl group, propyl group, isopropyl group, cyclopropyl group, cyclopropylmethyl group, methoxycarbonyl group, ethoxycarbonyl group, isopropoxycarbonyl group, cyclopropoxycarbonyl group, acetyl group, A propionyl group or a cyclopropylcarbonyl group is preferred.

R ¹⁰² and R ¹⁰³ are each independently preferably a hydrogen atom, a methyl group, a fluorine atom, a chlorine atom, or a bromine atom, and one of R ¹⁰² or R ¹⁰³ is a hydrogen atom, and the other is a methyl group or a fluorine atom. , A chlorine atom or a bromine atom is preferable.

R ¹⁰⁴ is preferably a hydrogen atom, a hydroxyl group, an acetoxy group, a propionyloxy group, or a cyclopropylcarbonyloxy group.

Typical examples of the compound represented by the general formula (2) include ticlopidine (2a) in which R ¹⁰¹ is a hydrogen atom, R ¹⁰² is an ortho-chloro group, R ¹⁰³ is a hydrogen atom, and R ¹⁰⁴ is a hydrogen atom, Clopidogrel (2b) wherein R ¹⁰¹ is a methoxycarbonyl group, R ¹⁰² is an ortho-chloro group, R ¹⁰³ is a hydrogen atom and R ¹⁰⁴ is a hydrogen atom, R ¹⁰¹ is a cyclopropylcarbonyl group, R ¹⁰² is an ortho-fluoro group, R 2-acetoxy-5- (α-cyclopropylcarbonyl-2-fluorobenzyl) -4,5,6,7-tetrahydrothieno [3,2-c] pyridine, wherein ¹⁰³ is a hydrogen atom and R ¹⁰⁴ is an acetoxy group, 5- (α-cyclopropylcarbonyl-2-fluorobenzyl) -2-hydroxy-4,5,6,7-tetrahydrothieno [3,2-c] pyridine, 2-acetoxy-5- (α- Toxicarbonyl-2-fluorobenzyl) -4,5,6,7-tetrahydrothieno [3,2-c] pyridine, 5- (α-methoxycarbonyl-2-fluorobenzyl) -2-hydroxy-4,5 Examples include 6,7-tetrahydrothieno [3,2-c] pyridine.

  The compound represented by the general formula (3) can be produced by the method described in JP-A-10-120649 or a method analogous thereto.

  The lower alkyl group, lower alkoxycarbonyl group, lower alkylcarbonyl group and halogen atom in the general formula (3) are the same as those in the general formula (2).

R ¹⁰⁵ includes a hydrogen atom, methyl group, ethyl group, propyl group, isopropyl group, cyclopropyl group, cyclopropylmethyl group, methoxycarbonyl group, ethoxycarbonyl group, isopropoxycarbonyl group, cyclopropoxycarbonyl group, acetyl group, A propionyl group or a cyclopropylcarbonyl group is preferred.

R ¹⁰⁶ and R ¹⁰⁷ are each independently preferably a hydrogen atom, a methyl group, a fluorine atom, a chlorine atom, or a bromine atom, and one of R ¹⁰² or R ¹⁰³ is a hydrogen atom, and the other is a methyl group or a fluorine atom. , A chlorine atom or a bromine atom is preferable.

R ¹⁰⁸ is preferably a hydrogen atom, a methyl group, an ethyl group, a propyl group, an isopropyl group, or a cyclopropyl group.

R ¹⁰⁹ is preferably a hydrogen atom, an acetyl group, a propionyl group or a cyclopropylcarbonyl group.

  Typical examples of the compound represented by the general formula (3) include 3-ethoxycarbonylmethylidene-1- (α-cyclopropylcarbonyl-2-fluorobenzyl) -4-mercaptopiperidine, 1- (2- Chloro-α-cyclopropylcarbonylbenzyl) -3-ethoxycarbonylmethylidene-4-mercaptopiperidine, 3-ethoxycarbonylmethylidene-1- (2-fluoro-α-methoxycarbonylbenzyl) -4-mercaptopiperidine, 1- (2-chloro-α-methoxycarbonylbenzyl) -3-ethoxycarbonylmethylidene-4-mercaptopiperidine, 3-carboxymethylidene-1- (α-cyclopropylcarbonyl-2-fluorobenzyl) -4-mercaptopiperidine, 3-Carboxymethylidene-1- (2-chloro- α-methoxycarbonylbenzyl) -4-mercaptopiperidine, 4-acetylthio-1- (α-cyclopropylcarbonyl-2-fluorobenzyl) -3-ethoxycarbonylmethylidenepiperidine, 4-acetylthio-1- (2-chloro- α-methoxycarbonylbenzyl) -3-ethoxycarbonylmethylidenepiperidine and the like.

  As the antiplatelet agent used in the present invention, a compound represented by the general formula (2) is preferable, among which ticlopidine, clopidogrel and 2-acetoxy-5- (α-cyclopropylcarbonyl-2-fluorobenzyl) -4. , 5,6,7-tetrahydrothieno [3,2-c] pyridine is more preferred.

  The daily dose for adults of the prophylactic / therapeutic agent for oral administration of thrombosis / embolism of the present invention varies depending on the type of antiplatelet drug combined with the compound represented by the general formula (1), but the general formula (1) The compound represented by the formula is 1 to 2000 mg, preferably 10 to 800 mg, more preferably 20 mg to 150 mg, and most preferably 30 to 120 mg. Hereinafter, the daily dose is a dose for an adult.

  The daily dose of the antiplatelet drug combined with the compound represented by the general formula (1) varies depending on the type of the antiplatelet compound, but for example, a compound represented by the general formula (2) or (3) The daily dose is 1 to 2000 mg, preferably 1 to 1000 mg, more preferably 5 to 600 mg. Aspirin is preferably 1 to 3000 mg, more preferably 10 to 2000 mg, and particularly preferably 30 to 1000 mg. Sarpogrelate is preferably 1 to 2000 mg, more preferably 10 to 1200 mg, and particularly preferably 30 to 900 mg. Limaprost is preferably 0.1 to 1000 μg, more preferably 1 to 600 μg, further 5 to 300 μg, and particularly preferably 10 to 300 μg. Cilostazol is preferably 1 to 2000 mg, more preferably 10 to 1000 mg, especially 30 to 600 mg.

  Antiplatelet drugs can be used in combination with the compound represented by the general formula (1) to obtain an excellent antithrombotic action even at a dose below the usual level. Here, the following normal dose refers to a dose smaller than the amount necessary to show a sufficient effect alone, and it is recommended as a dosage form to give the desired therapeutic effect when each component is administered alone to humans. It means a dose that does not reach the stated dose. The general-purpose dosage recommended for use to give the desired therapeutic effect can be easily known by those skilled in the art. The daily dosage is 81 mg for aspirin, 300 mg for sarpogrelate, and 15 μg for limaprost. 200 mg for cilostazol, 100-200 mg for ticlopidine, 50-75 mg for clopidogrel, 2-acetoxy-5- (α-cyclopropylcarbonyl-2-fluorobenzyl) -4,5,6,7-tetrahydrothieno [3,2 -C] 10-20 mg for pyridine.

  From this viewpoint, the daily dose of the antiplatelet drug combined with the compound represented by the general formula (1) is particularly preferably 40 to 81 mg aspirin, 150 to 300 mg sarpogrelate, 7.5 to 15 μg limaprost, 50 to cilostazol 50 to 200 mg, ticlopidine 50-100 mg, clopidogrel 25-50 mg or 2-acetoxy-5- (α-cyclopropylcarbonyl-2-fluorobenzyl) -4,5,6,7-tetrahydrothieno [3,2-c] pyridine 5 -10 mg. In this case, the daily dose of the compound represented by the general formula (1) used in combination with these antiplatelet drugs is preferably 30 to 120 mg.

  The form of the preparation may be a combination of the compound represented by the general formula (1) and the above antiplatelet drug. As a formulation, a tablet, a fine granule, a powder, a granule, and a capsule can be mentioned, A tablet and a capsule are preferable. These oral preparations contain pharmaceutically acceptable additives and require, for example, fillers, extenders, binders, disintegrants, dissolution promoters, wetting agents, lubricants, etc. It can be appropriately selected and used depending on the situation.

  Further, the preparation containing the compound represented by the general formula (1) and the preparation containing the antiplatelet drug may be separately packaged, and further packaged in a form in which the single dose of the two drugs is clear. . For example, it is good also as a kit for preventive treatment which made the preparation containing the compound represented by General formula (1), and the preparation containing an antiplatelet agent into one set.

  When actually administered, a mixture may be administered as in the above packaging form, or the compound represented by the general formula (1) and the antiplatelet drug may be administered separately. . Moreover, the prophylactic / therapeutic agent of the present invention may be administered by dividing the daily dose into 1 to 3 times.

  EXAMPLES The present invention will be specifically described below with reference to examples, but the present invention is not limited to these examples.

Example 1
As a compound represented by the general formula (1), N ^1- (5-chloropyridin-2-yl) -N ² -((1S, 2R, 4S) -4-[(dimethylamino) carbonyl] -2- { [(5-Methyl-4,5,6,7-tetrahydrothiazolo [5,4-c] pyridin-2-yl) carbonyl] amino} cyclohexyl) ethanediamide hydrochloride (compound A) and ticlopidine, The amount of thrombus was measured.

<Test>
Rats were orally dosed with 30 mg / kg of ticlopidine one day before the thrombus model. The same dose of ticlopidine was orally administered on the day of preparation of the thrombus model (two times in total). 1.5 hours after administration of ticlopidine, 2 mg / kg of Compound A was orally administered, and 15 minutes later, anesthesia with thiopental (100 mg / kg, ip) was performed. In addition, 0.5 mass% methylcellulose aqueous solution (0.5 mass% MC) was used as a solvent, and ticlopidine and Compound A were dissolved in 0.5 mass% MC.
An arteriovenous (AV) shunt was prepared by connecting a 20 cm long copper wire between the carotid artery and jugular vein of anesthetized rats. Two hours after administration of ticlopidine, that is, 30 minutes after administration of Compound A, blood circulation was opened in the shunt, and 12 minutes later, a thrombus formed in the shunt was taken out. The amount of thrombus protein was determined by the Bradford method to obtain the amount of thrombus.

<Result>
The obtained results are shown in Table 1. In a 0.5% by weight MC-treated control animal, about 430 mg of thrombus was formed. With Compound A or ticlopidine alone, thrombus formation was suppressed to 275 mg and 210 mg, respectively, but the inhibition rates were only 36% and 51%. When Compound A and ticlopidine were used in combination, the amount of thrombus was reduced to 109 mg and the inhibition rate of thrombus formation was increased to 75%, and the combined effect was recognized. The combined use of Compound A and ticlopidine showed potent antithrombotic action at doses lower than those required for ticlopidine alone to be fully effective.

Example 2
Using Compound A as a representative example of the compound represented by the general formula (1), metabolic stability against the liver metabolic enzyme cytochrome P450 (CYP) was measured.

<Test>
This test is based on Z. Yan and G. W. According to the method of Caldwell, "Methods in Pharmacology and Toxicology, Optimization in Drug Discovery: In Vitro Methods", page 255-310 (2004) (Method), according to Humana Press Inc. (To). CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, and CYP3A4 microsomes (SUPERSOMES: manufactured by BD GENTEST (Woburn, USA)).

<Result>
CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19 and CYP2E1-dependent compound A metabolites are not detected, and CYP2D6 and CYP3A4-dependent compound A metabolism rates vary depending on the metabolite, but It was 0.81 pmol / pmol CYP / min. Therefore, Compound A was not easily metabolized by CYP and was stable.

Example 3
Using Compound A as a representative example of the compound represented by the general formula (1), the inhibitory action on the liver metabolic enzyme cytochrome P450 (CYP) was measured.

<Test>
This test is based on Z. Yan and G. W. According to the method of Caldwell, “Methods in Pharmacology and Toxicology, Optimization in Drug Discovery: In Vitro Methods”, 231-244 (2004) (No.), TE, according to TE. This was performed using human liver microsomes manufactured by (Kansas City, USA). CYP used was 1A2, 2A6, 2B6, 2C8 / 9, 2C19, 2D6, 2E1 and 3A4.

<Result>
For any CYP, the inhibitory effect was 100 μmol / L or more in terms of IC50 value. Therefore, it is considered that administration of Compound A to humans does not inhibit CYP.

Claims (21)

An active ingredient is a compound represented by the general formula (1) and an anti-platelet drug selected from aspirin, sarpogrelate, limaprost, cilostazol, a compound represented by the general formula (2) and a compound represented by the general formula (3) Oral prophylactic and therapeutic agent for thrombus and embolism.
Wherein Q ¹ is a 4,5,6,7-tetrahydrothiazolo [5,4-c] pyridin-2-yl group, which may have 1 to 2 substituents, 6,7-tetrahydrothiazolo [4,5-c] pyridin-2-yl group, 4,5,6,7-tetrahydrothieno [2,3-c] pyridin-2-yl group, 4,5,6 , 7-tetrahydrooxazolo [5,4-c] pyridin-2-yl group, 4,6-dihydro-5H-pyrrolo [3,4-d] thiazol-2-yl group, dihydropyrrolo [3,4 d] pyrimidin-2-yl group, 4,5,6,7-tetrahydrothiazolo [4,5-d] pyridazin-2-yl group, 4,5,6,7-tetrahydrooxazolo [4.5- d] pyridazin-2-yl group, 4,5,6,7-tetrahydrobenzo [d] thiazol-2- Indicates group or dihydro -4H- pyrano [4,3-d] thiazol-2-yl group;
Q ² is an alkylene group having 1 to 8 carbon atoms or a group — (CH ₂ ) pA— (CH ₂ ) q— (in the group, p and q are each independently an integer of 1 to 3 (provided that p And A represents a oxygen atom, a nitrogen atom, a sulfur atom, —SO—, —SO ₂ —, or —NH—.
Indicates;
R ¹ and R ² are each substituted with a ring containing Q ² and each independently represents a hydrogen atom, hydroxyl group, amino group, carboxyl group, oxo group, alkyl group, halogenoalkyl group, acyl group, alkoxy group, alkoxyalkyl group , Hydroxyalkyl group, carboxyalkyl group, alkoxycarbonyl group, alkoxycarbonylalkyl group, optionally substituted acylamino group, acylaminoalkyl group, aminoalkyl group, N-alkylaminoalkyl group, N, N-dialkyl Aminoalkyl group, N-alkoxycarbamoyl group, N-alkyl-N-alkoxycarbamoyl group, carbazoyl group optionally having 1 to 3 alkyl groups, alkylsulfonyl group, alkoxycarbonylamino group, carbamoyl group, alkyl group N-alkyl which may have a substituent on Moyl group, N, N-dialkylcarbamoyl group which may have a substituent on the alkyl group, alkylsulfonylamino group, alkoxycarbonylalkylsulfonyl group, carboxyalkylsulfonyl group, alkoxycarbonylacyl group, alkoxyalkylsulfonyl group or substituted 3 to 6-membered heterocyclic carbonyl group which may have a group. );
Q ³ is a carbonyl group, a sulfonyl group, —C (═O) —C (═O) —NH—, —C (═S) —C (═O) —NH—, —C (═O) —C (= S) -NH- or -C (= S) -C (= S) -NH- is shown;
Q ⁴ may have 1 to 2 substituents, phenyl group, naphthyl group, pyridyl group, pyrimidinyl, pyrazinyl group, pyridazinyl group, indolyl group, benzothienyl group, benzofuranyl group, benzoimidazolyl group, quinolyl group, An isoquinolyl group, a cinnolyl group, a thienyl group, a furyl group, a thiazolyl group, an oxazolyl group or a styryl group; ),
(Wherein R ¹⁰¹ represents a hydrogen atom, a lower alkyl group, a lower alkoxycarbonyl group or a lower alkylcarbonyl group, R ¹⁰² and R ¹⁰³ each independently represent a hydrogen atom, a lower alkyl group or a halogen atom, R ¹⁰⁴ represents a hydrogen atom, a hydroxyl group or a lower alkylcarbonyloxy group).
(Wherein R ¹⁰⁵ represents a hydrogen atom, a lower alkyl group, a lower alkoxycarbonyl group or a lower alkylcarbonyl group, R ¹⁰⁶ and R ¹⁰⁷ each independently represents a hydrogen atom, a lower alkyl group or a halogen atom; R ¹⁰⁸ represents a hydrogen atom or a lower alkyl group, and R ¹⁰⁹ represents a hydrogen atom or a lower alkylcarbonyl group.)   The preventive or therapeutic agent for oral administration of thrombus / embolus according to claim 1, wherein the antiplatelet drug is a compound represented by the general formula (2). The compound represented by formula (2) is a compound (ticlopidine) in which R ¹⁰¹ is a hydrogen atom, R ¹⁰² is an ortho-chloro group, R ¹⁰³ is a hydrogen atom, and R ¹⁰⁴ is a hydrogen atom. The preventive or therapeutic agent for oral administration of the thrombus / embolus described. The compound represented by the general formula (2) is a compound (clopidogrel) in which R ¹⁰¹ is a methoxycarbonyl group, R ¹⁰² is an ortho-chloro group, R ¹⁰³ is a hydrogen atom, and R ¹⁰⁴ is a hydrogen atom. The preventive or therapeutic agent for oral administration of thrombus or embolus according to 2. The compound represented by the general formula (2) is a compound in which R ¹⁰¹ is a cyclopropylcarbonyl group, R ¹⁰² is an ortho-fluoro group, R ¹⁰³ is a hydrogen atom and R ¹⁰⁴ is an acetoxy group (2-acetoxy-5- ( The preventive or therapeutic agent for orally administered thrombus / embolus according to claim 1 or 2, which is α-cyclopropylcarbonyl-2-fluorobenzyl) -4,5,6,7-tetrahydrothieno [3,2-c] pyridine).   The preventive or therapeutic agent for oral administration of thrombus / embolus according to claim 1, wherein the antiplatelet drug is a compound represented by the general formula (3).   The prophylactic / therapeutic agent for oral administration of thrombus / embolus according to claim 1, wherein the antiplatelet drug is aspirin.   The prophylactic / therapeutic agent for oral administration of thrombus / embolus according to claim 1, wherein the antiplatelet agent is sarpogrelate.   The prophylactic / therapeutic agent for oral administration of thrombosis / embolism according to claim 1, wherein the antiplatelet agent is limaprost.   The prophylactic / therapeutic agent for oral administration of thrombus / embolism according to claim 1, wherein the antiplatelet drug is cilostazol.   The preparation containing the compound represented by the general formula (1) and the preparation containing an antiplatelet drug are packaged separately, and further, the single dose of the two drugs is packaged in a clear form. The prophylactic / therapeutic agent for oral administration of a thrombus / embolus according to claim 1.   The thrombus / embolism according to any one of claims 1 to 10, which is a kit comprising a preparation containing the compound represented by the general formula (1) and a preparation containing an antiplatelet agent. Prophylactic and therapeutic agent for oral administration.   The preventive or therapeutic agent for oral administration of thrombus / embolus according to any one of claims 1 to 10, wherein the form of the preparation is a combination of a compound represented by the general formula (1) and an antiplatelet drug. .   The prophylactic / therapeutic agent for oral administration of thrombus / embolus according to claim 1, wherein the antiplatelet drug is administered at a dose usually below.   The preventive or therapeutic agent for oral administration of thrombus / embolus according to claim 3, wherein the daily dose of the compound represented by the general formula (1) is 30 to 120 mg and the daily dose of ticlopidine is 50 to 100 mg.   The preventive or therapeutic agent for oral administration of thrombus / embolus according to claim 4, wherein the daily dose of the compound represented by the general formula (1) is 30 to 120 mg and the daily dose of clopidogrel is 25 to 50 mg.   The daily dose of the compound represented by the general formula (1) is 30 to 120 mg, 2-acetoxy-5- (α-cyclopropylcarbonyl-2-fluorobenzyl) -4,5,6,7-tetrahydrothieno The preventive or therapeutic agent for oral administration of thrombus / embolus according to claim 5, wherein the daily dose of [3,2-c] pyridine is 5 to 10 mg.   The preventive or therapeutic agent for oral administration of thrombus / embolus according to claim 7, wherein the daily dose of the compound represented by the general formula (1) is 30 to 120 mg and the daily dose of aspirin is 40 to 81 mg.   The preventive or therapeutic agent for oral administration of thrombus / embolus according to claim 8, wherein the daily dose of the compound represented by the general formula (1) is 30 to 120 mg and the daily dose of sarpogrelate is 150 to 300 mg.   The prophylactic / therapeutic agent for oral administration of thrombus / embolus according to claim 9, wherein the daily dose of the compound represented by the general formula (1) is 30 to 120 mg and the daily dose of limaprost is 7.5 to 15 µg. .   The preventive or therapeutic agent for oral administration of thrombus / embolus according to claim 10, wherein the daily dose of the compound represented by the general formula (1) is 30 to 120 mg and the daily dose of cilostazol is 50 to 200 mg.